The treatment of obesity can no longer be reduced to a simplistic view of weight loss.
Metabolic adaptation leads to systematic weight regain following weight-loss efforts, and …

Obesity, a chronic disease associated with significant morbidity (1) and excess mortality (2),
has become a global epidemic with a significant impact on healthcare systems and society …

Introduction The recent approval in the USA (Food and Drug Administration), Canada
(Health Canada), UK (Medicines and Healthcare products Regulatory Agency), and EU …

Obesity is a chronic, relapsing disease associated with multiple complications and a
substantial morbidity, mortality and health care burden. Pharmacological treatments for …

Semaglutide (▼ Ozempic solution for injection,▼ Rybelsus tablets—Novo Nordisk) was
initially granted market authorisation for the treatment of type 2 diabetes as an adjunct to diet …

Semaglutide 2· 4 mg once weekly, an anti-obesity medication now submitted to regulators
across the USA and Europe, is generating much excitement and attention about the amount …

Abstract Losses of 5–10% or more of initial body weight are associated with improvements
in obesity-related comorbidities. However, attaining and sustaining this level of weight loss …

Obesity negatively impacts patients' health-related quality of life (QOL) and is associated
with a range of complications such as type 2 diabetes (T2D), cardiovascular disease, and …

Background Management guidelines for obesity suggest maintaining a minimum of 5% body
weight reduction to help prevent or lower the risk of developing conditions such as …

Objective: To review the efficacy, safety, and role of the glucagon-like peptide-1 (GLP-1)
receptor agonist semaglutide for chronic weight management. Data Sources: A literature …